Our Take
Daiichi has a proven platform (Enhertu, Datroway) and three late-stage candidates in the pipeline, but the entire strategy rests on ADCs in a space where competition is intensifying and clinical setbacks are real.
Why it matters
Oncology pharma R&D spending signals where capital flows and which technological bets are winning. Daiichi's $18.5B five-year commitment and explicit 2035 target show how incumbents are racing to lock in ADC dominance before next-generation platforms mature.
Do this week
Pharma business dev: audit your competitive ADC pipeline against Daiichi's three late-stage assets (ifinatamab, raludotatug, patritumab) and confirm your target indications are not already claimed or overserved.
Daiichi Sankyo Commits $18.5B to Oncology Expansion Through 2030
Daiichi Sankyo announced a five-year business plan centered on becoming a top-five global oncology company by 2035, backed by $18.5 billion in R&D spending (per company filing). The strategy pivots on maximizing its proprietary DXd antibody-drug conjugate (ADC) platform, which has already produced Enhertu, a blockbuster approved across breast, gastric, and lung cancers developed with AstraZeneca.
Two existing products anchor growth: Enhertu and Datroway (a TROP2-directed ADC, also from the Daiichi-AstraZeneca partnership). The company expects these two drugs, plus a pipeline of DXd-based candidates, to generate more than 3 trillion yen ($19.1 billion) in peak sales (company-reported).
Three late-stage ADCs are expected to launch within five years: ifinatamab deruxtecan (B7-H3-directed, in phase 3 for small cell lung cancer under a $5.5 billion Daiichi-Merck collaboration signed in 2023), raludotatug deruxtecan (CDH6-directed, for ovarian cancer), and patritumab deruxtecan (HER3-directed, for HR-positive breast cancer). Ifinatamab initially faced an FDA partial clinical hold in December following unexpected deaths from interstitial lung disease, a known toxicity class effect of DXd therapies, but the hold was lifted in January with commitments to stricter enrollment criteria and more frequent safety reviews.
Beyond current-generation ADCs, Daiichi is investing in next-generation payloads designed to overcome DXd resistance, STING-pathway activators for immune stimulation, and broader platforms including multi-specific antibodies, targeted protein degraders, and siRNA therapies. The company expects promising signals from these experimental platforms by 2030 and revenue contribution by 2035 (per company guidance). Daiichi also plans to deploy AI to cut 200 billion yen ($1.3 billion) in cumulative costs over the five-year window (company-reported).
ADC Leadership Is Daiichi's Bet, But Competition and Clinical Risk Are Real
Daiichi has built structural dominance in ADCs—a class that combines monoclonal antibody targeting with cytotoxic payload delivery. Enhertu's multi-indication approval and blockbuster status validate the DXd platform's versatility. But the 2035 target depends on three conditions: successful launches of late-stage candidates, sustained growth from existing blockbusters, and meaningful progress on next-generation technologies before 2035.
Two risks loom. First, the ADC field is crowded. Established pharma (Roche, Eli Lilly, Pfizer) and biotechs are developing rival ADCs, eroding Daiichi's first-mover advantage. Second, clinical setbacks are not hypothetical. Patritumab deruxtecan failed to hit overall survival in lung cancer and was withdrawn from regulatory review; the FDA flagged safety signals in ifinatamab's program. Even assets with defensible science can stumble in late-stage trials. Daiichi's roadmap depends on flawless execution at a time when oncology ADC outcomes are increasingly scrutinized.
The $19.1 billion peak-sales projection reflects company modeling, not independent validation. Whether the pipeline delivers at that magnitude—and whether it does so by 2035—remains unproven.
What to Watch in Daiichi's 2025 Catalysts
Track three near-term milestones. Ifinatamab phase 3 enrollment and interim safety readouts will show whether Merck and Daiichi can sustain trial momentum after the hold. Datroway label expansion in solid tumors will indicate whether a second DXd franchise can achieve Enhertu-scale sales. Raludotatug and patritumab clinical data will confirm whether DXd potency translates beyond HER2 and TROP2 targets. Any significant delay or negative readout compresses the 2035 timeline and forces reallocation within the R&D budget.
For partners considering oncology collaboration with Daiichi, confirm whether the company's 2030 technology milestones are contractually binding and what IP rights attach to next-generation payloads if they emerge earlier than expected.